Non-Invasive Treatments That Restore Cognitive Function


ERASING BARRIERS

A NEW Platform TO TREAT CNS

 

ExQor's multi-patented bio-platform enables new types of CNS therapeutics that non-invasively cross the otherwise impassable blood brain barrier. For example:


There are currently no sensitive MRI biomarkers for early diagnosis and accurate prediction of developing neurodegenerative diseases, for example, the lack of high resolution MRI markers of activated microglia cells in CNS. This level of molecular imaging is now only yielded by PET. ExQor is developing non-radioactive imaging agents that enable conventional MRI to have similar molecular level resolution as PET and without using radioligands. This ExQor breakthrough will enable thousands more clinics to do early and more accurate detection of these diseases using their conventional MRI systems.


Increased diagnostic accuracy leads to improved patient treatment and outcomes. ExQor also is joining together its novel MR imaging agents with targeting agents such as antibodies to target and image specific regions or cells in the brain such as activated microglia cells. Such improved imaging information enables ordinary clinics to better diagnose and monitor patient progress.


The ultimate in patient treatment is to be able to target, image, and treat specific regions and/or cells in the brain and using just a single drug. ExQor is developing this all-in-one drug. ExQor is combining together its unique MR imaging agents and the targeting agents with ExQor's large molecule biologics. ExQor's CNS biologics can restore synaptic function and cause new nerve cells to be generated, thereby restoring cognitive functions. The net result will be precise and enhanced treatments that improve patient outcomes and quality of life.

 

Imaging and Targeting Activated Microglia in CNS

 

 

 

 

 

 

 

 

 

 

 

© 2022 EXQOR TECHNOLOGIES, INC. ALL RIGHTS RESERVED